New hope for 10x’ preliminary injunction after EPO Opposition Division ruling | Patent at issue concerns single-cell spatial ...

Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

Bank of New York Mellon Corp lowered its stake in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 13.5% in the ...

Shares of 10x Genomics, Inc. (NASDAQ:TXG – Get Free Report) have received a consensus rating of “Hold” from the seventeen analysts that are currently covering the company, Ratings reports. One ...

Single-cell transcriptomics has revolutionized the study of cellular diversity and function by enabling gene expression ...

Popcorn is one of my all-time favorite snacks, especially now that I have to eat gluten-free. It's a quick way to fill me up without having to worry about what's in it. Whether it's buttery movie ...

PLEASANTON, Calif., March 3, 2025 /PRNewswire/ -- 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.

Functional genomics uses genomic data to study gene and protein expression and function on a global scale (genome-wide or system-wide), focusing on gene transcription, translation and protein ...

"By transforming questions about metabolism into a genomics challenge, we were able to draw a 'wiring map' of adult worm metabolism that revealed numerous novel insights." "The most exciting part ...

As the Uniswap price fluctuates, investors are eyeing DeFi tokens for 10x gains in 2025. Remittix, Near Protocol, Uniswap, and Aave stand out as top contenders. Let us highlight each top altcoins ...

Imagine an AI system capable of guiding a robot to manipulate physical objects as effortlessly as it navigates software menus. Such seamless integration of digital and physical tasks has long been the ...